Objective To conduct a bibliometric and visual analysis of global literature on cardiovascular immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) in cancer treatment, and to explore the research status, hotspots, and future trends in this field.

Methods The Web of Science Core Collection (WOSCC) database was utilized to retrieve and screen relevant literature. CiteSpace software was employed for visual analysis of countries, institutions, authors, and keywords.

Results A total of 1, 350 articles were retrieved, with an annual increase in publication volume. The United States dominated in terms of national, institutional, and author contributions, while European countries and institutions demonstrated close collaborative networks. Keyword analysis and cited reference mapping revealed an evolution of research hotspots: from initial mechanistic investigations to monoclonal antibody applications, and subsequently to safety concerns. Current lresearch focuses on ICI monoconal antibody combination therapy for malignancies and cardiovascular irAEs, particularly fatal myocarditis, which has emerged as a prominent topic.

Conclusion ICIs monoclonal antibody therapies and their associated cardiovascular irAEs, especially combination therapies and life-threatening myocarditis, represent key research frontiers. Investigations into drug combination strategies and fatal myocarditis may guide future research directions.